The European Medicines Agency (EMA) granted the qualification of “Small and Medium-Sized Enterprises” (SME) to Microviable Therapeutics. The European Medicines Agency (EMA) provides incentives and support for micro, small and medium-sized enterprises (SMEs) that are [...]
Checkout our new GutAlive® !! The unique user-friendly, high-capacity device for stool collection sampling and transport in anaerobic conditions that ensures sample stability, microbiota viability and preserves DNA integrity. GutAlive® preserves the [...]
Claudio Hidalgo Cantabrana, PhD, CEO at Microviable, and our CBO, Rafael M. Permuy, MBA, will be attending BIO-Europe event in Leipzig, Germany, from October 24th to 26th. BIO-Europe® is the preeminent partnering conference for the [...]
Welcome Pilar Manrique, PhD on board. Pilar obtained her undergraduate degree in Biotechnology at Universidad Francisco de Vitoria (2009) and her doctorate at Montana State University (2018). Pilar has worked over ten years studying the [...]
Microviable Therapeutics will be presenting at I Asturias International Meeting on Clinical Microbiology and Infectious Disease (AIMID 2022) on September 22-23. Claudio Hidalgo, CEO at Microviable, will discuss the use of “Microbiome-derived biotherapeutic products for [...]
Microviable will be attending AIMID 2022 (I Asturias International Meeting on Clinical Microbiology and Infectious Disease).
Microviable Therapeutics will participate and sponsor of AIMID 2022 (I Asturias International Meeting on Clinical Microbiology and Infectious Disease) that will take place in Oviedo (Asturias) on September 22-23, 2022. Microviable is honored to become [...]
Alejandro Lucia, researcher at the European University and collaborator of Microviable Therapeutics, National Award for Research in Sports Medicine.
It is always a pleasure to work with prestigious researchers. Congratulations Alejandro Lucia! for the award received. A group of ten researchers from various institutions, including Alejandro Lucia, a researcher at the European University and [...]
Microviable announces 1.5 million € investment to advance the company´s microbiota-derived biotherapeutic products.
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL. Microviable [...]
Our CEO Claudio Hidalgo will be attending the Pharmabiotics Event 2022 taking place on April 20th-21st at Lyon. The Pharmabiotics Conference brings together players from academia and industry and it is an incredible opportunity to [...]
As part of our growth and consolidation as a microbiome company focused on therapeutics we have several openings to join our team! Are you ready to rock? Check out our careers section and submit [...]